Document is current
Any future updates will be listed below
-
Authors
Matoba, Yusuke
Devins, Kyle M.
Milane, Lara
Manning, William B.
Mazina, Varvara
Yeku, Oladapo O.
Rueda, Bo R. https://orcid.org/0000-0001-9489-8699
-
Funding
Funding for this research was provided by:
Nile Albright Research Foundation (Nile Albright Research Foundation)
Vincent Memorial Hospital Foundation (Vincent Memorial Hospital Foundation)
- License Information
-
More Information
Article History
Received: 2 October 2023
Accepted: 2 April 2024
First Online: 24 April 2024
Declarations
:
: Not Applicable.
: Not Applicable.
: Not Applicable.
: O.O.Y reports grants from Ascendis Pharma A/S, Avenge Bio, Inc., Immunocore Limited, Duality Biologics, Merck Sharp & Dohme Corporation, Pionyr Immunotherapeutics Inc., ProfoundBio, and the Department of Defense. Consulting fees from Celldex Therapeutics, GIMV NV, TigaTx Inc. Advisory board role at hC Bioscience. In addition, he has a patent pending for MUC16 Directed Antibodies for therapeutic applications, and a patent pending for Human Artificial Chromosomes for therapeutic applications. None of these disclosures have no direct relevance on the current review. B.R.R. reports serving on the advisory board for VincenTech and does not have a direct bearing to the current review. All other authors declare no COI related to this review.
